When you are in treatment with your provider, they will create a custom treatment plan for you
Start conservatively and let your provider adjust based on response rather than pursuing maximum doses
As demand grows across the pharmaceutical, nutraceutical, cosmetic, and functional food industries, glutathione has become an increasingly important ingredient in a wide range of formulations
The Future of Thymosin Alpha-1 Research Awareness of immune health has skyrocketed in the last 10 years
Summary of REDEFINE 1 and REDEFINE 2 trials with CagriSema, presented this week at #ADA2025 and published in NEJM: REDEFINE 1: 3,417 participants with obesity or overweight (without diabetes) treated with CagriSema achieved a 22.7% weight loss after 68 weeks, compared to 2.3% with placebo 40.4% of participants on CagriSema achieved a weight loss of 25% or more The weight loss was slightly below the company's initial expectations of at least 25% REDEFINE 2: 1,206 participants with obesity or overweight and type 2 diabetes treated with CagriSema achieved a 15.7% weight loss after 68 weeks, best in the category thus far , compared to 3.1% with placebo 89.7% of participants achieved a weight loss of 5% or more Mean HbA1c reduction of 2.07% Article links: nejm.org/doi/full/10.10 nejm.org/doi/full/10.10 Summary of REDEFINE 1 and REDEFINE 2 trials with CagriSema, presented this week at #ADA2025 and published in NEJM: REDEFINE 1: 3,417 participants with obesity or overweight (without diabetes) treated with CagriSema achieved a 22.7% weight loss after 68 weeks, compared to 2.3% with placebo 40.4% of participants on CagriSema achieved a weight loss of 25% or more The weight loss was slightly below the company's initial expectations of at least 25% REDEFINE 2: 1,206 participants with obesity or overweight and type 2 diabetes treated with CagriSema achieved a 15.7% weight loss after 68 weeks, best in the category thus far , compared to 3.1% with placebo 89.7% of participants achieved a weight loss of 5% or more Mean HbA1c reduction of 2.07% Article links: nejm.org/doi/full/10.10 nejm.org/doi/full/10.10 Hopefully primary prevention in normal weight is next Pharma has obesity in its sights
doi: 10.1111/jpi.12216 87 XiHHuangLQiuLLiSYanYDingYet al
